Javascript must be enabled to continue!
Statin Use, Incident Dementia and Alzheimer Disease in Elderly African Americans
View through CrossRef
<p><strong>Objective: </strong>To investigate the association between statin use, incident dementia, and Alzheimer disease (AD) in a prospective elderly African American cohort.</p><p><strong>Design: </strong>Two stage design with a screening interview followed by a comprehensive in-home assessment conducted over an eight-year period. Diagnoses of incident AD and dementia were made by consensus. Statin use was collected at each evaluation. Measurements of low-density lipoprotein cholesterol (LDL), C-reactive protein (CRP) and APOE genotype were obtained from baseline blood samples. Logistic regression models were used to test the association of statin use on incident dementia and AD and its possible association with lipid and CRP levels.</p><p><strong>Setting: </strong>Indianapolis, Indiana</p><p><strong>Participants: </strong>From an original cohort of 2629 participants, a subsample of 974 African Americans aged >70 years with normal cognition, at least one follow up evaluation, complete statin information, and biomarker availability were included.</p><p><strong>Main Outcome Measures: </strong>Incident dementia and incident AD.</p><p><strong>Results: </strong>After controlling for age at diagnosis, sex, education level, presence of the APOE ε4 allele and history of stroke for the incident dementia model, baseline use of statins was associated with a significantly decreased risk of incident dementia (OR=.44, <em>P</em>=.029) and incident AD (OR=.40, <em>P</em>=.029). The significant effect of statin use on reduced AD risk and trend for dementia risk was found only for those participants who reported consistent use over the observational period (incident AD: <em>P</em>=.034; incident dementia: <em>P</em>=.061). Additional models found no significant interaction between baseline statin use, baseline LDL, or CRP level and incident dementia/AD.</p><p><strong>Conclusions: </strong>Consistent use of statin medications during eight years of follow-up resulted in significantly reduced risk for incident AD and a trend toward reduced risk for incident dementia. <em>Ethn Dis.</em>2015;25(3):345-354.</p>
Ethnicity and Disease Inc
Title: Statin Use, Incident Dementia and Alzheimer Disease in Elderly African Americans
Description:
<p><strong>Objective: </strong>To investigate the association between statin use, incident dementia, and Alzheimer disease (AD) in a prospective elderly African American cohort.
</p><p><strong>Design: </strong>Two stage design with a screening interview followed by a comprehensive in-home assessment conducted over an eight-year period.
Diagnoses of incident AD and dementia were made by consensus.
Statin use was collected at each evaluation.
Measurements of low-density lipoprotein cholesterol (LDL), C-reactive protein (CRP) and APOE genotype were obtained from baseline blood samples.
Logistic regression models were used to test the association of statin use on incident dementia and AD and its possible association with lipid and CRP levels.
</p><p><strong>Setting: </strong>Indianapolis, Indiana</p><p><strong>Participants: </strong>From an original cohort of 2629 participants, a subsample of 974 African Americans aged >70 years with normal cognition, at least one follow up evaluation, complete statin information, and biomarker availability were included.
</p><p><strong>Main Outcome Measures: </strong>Incident dementia and incident AD.
</p><p><strong>Results: </strong>After controlling for age at diagnosis, sex, education level, presence of the APOE ε4 allele and history of stroke for the incident dementia model, baseline use of statins was associated with a significantly decreased risk of incident dementia (OR=.
44, <em>P</em>=.
029) and incident AD (OR=.
40, <em>P</em>=.
029).
The significant effect of statin use on reduced AD risk and trend for dementia risk was found only for those participants who reported consistent use over the observational period (incident AD: <em>P</em>=.
034; incident dementia: <em>P</em>=.
061).
Additional models found no significant interaction between baseline statin use, baseline LDL, or CRP level and incident dementia/AD.
</p><p><strong>Conclusions: </strong>Consistent use of statin medications during eight years of follow-up resulted in significantly reduced risk for incident AD and a trend toward reduced risk for incident dementia.
<em>Ethn Dis.
</em>2015;25(3):345-354.
</p>.
Related Results
Race, polygenic risk and their association with incident dementia among older US adults
Race, polygenic risk and their association with incident dementia among older US adults
AbstractDementia incidence increases steadily with age at rates that may vary across racial groups. This racial disparity may be attributable to polygenic risk, as well as lifestyl...
Imaging breakthroughs in dementia: Pioneering 3D T1-weighted MPRAGE vs. routine spin echo with a focus on Alzheimer's disease
Imaging breakthroughs in dementia: Pioneering 3D T1-weighted MPRAGE vs. routine spin echo with a focus on Alzheimer's disease
Background. Dementia, a spectrum of neurocognitive disorders, leads to progressive cognitive and functional decline, primarily affecting memory and executive functions. Among the m...
Abstract P1-15-03: Assessing the association of statins with clinical outcomes in women with breast cancer
Abstract P1-15-03: Assessing the association of statins with clinical outcomes in women with breast cancer
Abstract
Background: A growing number of studies are claiming lipid-lowering medications (LLMs) primarily statins have anticancer properties to inhibit proliferation...
Statin use is associated with lower risk of new onset dementia in patients with heart failure
Statin use is associated with lower risk of new onset dementia in patients with heart failure
Abstract
Background
Increasing number of heart failure (HF) patients diagnosed with dementia due to improved treatment and aging...
Predictors of statin adherence in primary care using real-world data
Predictors of statin adherence in primary care using real-world data
Abstract
Purpose
The objective of this study was to identify predictors of statin adherence in the primary and secondary preven...
1228-P: Comparison between Combination of Low- or Moderate-Intensity Statin with Ezetimibe and High-Intensity Statin Monotherapy for Primary Prevention of Cardiovascular Disease and All-Cause Mortalities in Patients with Type 2 Diabetes—A Propensity-Match
1228-P: Comparison between Combination of Low- or Moderate-Intensity Statin with Ezetimibe and High-Intensity Statin Monotherapy for Primary Prevention of Cardiovascular Disease and All-Cause Mortalities in Patients with Type 2 Diabetes—A Propensity-Match
Background and Aims: Here, we compared the effects of combination therapy of low- or moderate-statin with ezetimibe and high-intensity statin monotherapy in patients with type 2 di...
MBI‐apathy, ApoEɛ2, and risk for Alzheimer disease dementia
MBI‐apathy, ApoEɛ2, and risk for Alzheimer disease dementia
AbstractBackgroundApathy, characterized by decreased interest, initiative, and emotional reactivity, is amongst the most common neuropsychiatric symptoms in dementia. However, apat...
Statin use and the risk of Acute Myeloid Leukemia: A retrospective propensity-matched cohort study
Statin use and the risk of Acute Myeloid Leukemia: A retrospective propensity-matched cohort study
Abstract
Background: Statins, among the most widely prescribed medications worldwide, inhibit the mevalonate pathway and...

